CIHR Canadian HIV trials network coinfection and concurrent diseases core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 24, Issue 4, 2013, Pages 217-238

  Hull, Mark ^a   Klein, Marina ^b   Shafran, Stephen ^c   Tseng, Alice ^d   Giguère, Pierre ^e   Côté, Pierre ^f   Poliquin, Marc ^f   Cooper, Curtis ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f Clinique Medicale du Quartier Latin   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antivirals; Direct acting antivirals; HCV; HIV; Pharmacokinetics

Indexed keywords

ANTIRETROVIRUS AGENT; BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT; CYTOPENIA; DISEASE COURSE; GENOTYPE; HEALTH CARE QUALITY; HEALTH ECONOMICS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDICAL HISTORY; MIXED INFECTION; NONHUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; RETREATMENT; SEXUAL TRANSMISSION; VIRAL CLEARANCE;

EID: 84892175028     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2013/781410     Document Type: Article

References (214)

1. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (London, England) 2012; 26:335-43.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271-8.
3. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D: A: D study. Arch Intern Med 2006; 166:1632-41.
4. Coffin CS, Fung SK, Ma MM, Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012; 26:917-38.
5. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012; 26:359-75.
6. Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS (London, England) 2007; 21:685-92.
7. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160:659-65.
8. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Ann Rev Med 2008; 59:473-85.
9. Klein MB, Rollet K, Saeed S, et al. HIV and hepatitis C virus co-infection in Canada: Challenges and opportunities for reducing preventable morbidity and mortality. HIV Med 2013; 14:10-20.
10. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
11. Hepatitis C - global prevalence (update): World Health Organization, 2003. (Accessed October 16, 2013).
12. Epidemiology of Acute Hepatitis C Infection in Canada: Results from the Enhanced Hepatitis Strain Surveillance System (EHSSS). Public Health Agency of Canada, 2008. (Accessed May 17, 2013).
13. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007. In: Community Acquired Infections Division CDa IPB. Ottawa: Public Health Agency of Canada, 2007.
14. Althoff KN, Eichelberger M, Gange SJ, et al. Seroincidence of 2009 H1N1 infection in HIV-infected and HIV-uninfected women prior to vaccine availability. AIDS (London, England) 2011; 25:1229-32.
15. Parent R, Alary M, Morissette C, Roy E, Leclerc P, Allard PR. Surveillance des maladies infectieuses chez les utilisateurs de drogue par injection: épidémiologie du VIH de 1995 à 2008: Institut National de Santé Publique. 2009. (Accessed October 16, 2013).
16. Public Health Agency of Canada. HIV/AIDS Among Aboriginal People in Canada. HIV/AIDS Epi Updates, July 2010. Ottawa: Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control, 2010.
17. Saskatchewan Ministry of Health. Saskatchewan HIV Strategy. 2012 (Accessed April 2013).
18. Wood E, Montaner JS, Li K, et al. Burden of HIV infection among Aboriginal injection drug users in Vancouver, British Columbia. Am J Public Health 2008; 98:515-9.
19. Calzavara L, Ramuscak N, Burchell AN, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities. CMAJ 2007; 177:257-61.
20. Zakaria D, Thompson JM, Jarvis A, Borgatta F. Summary of emerging findings from the 2007 National Inmate Infectious Diseases and Risk-Behaviours Survey. Correctional Service Canada, 2010.
21. Miller CL, Johnston C, Spittal PM, et al. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36:737-42.
22. Spittal PM, Pearce ME, Chavoshi N, et al. The Cedar Project: High incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities. BMC Publ Health 2012; 12:632.
23. Collins CL, Kerr T, Tyndall MW, et al. Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users. Can J Public Health 2005; 96:344-47.
24. Wood E, Kerr T, Spittal PM, et al. The potential public health and community impacts of safer injecting facilities: Evidence from a cohort of injection drug users. J Acquir Immune Defic Syndr 1999; 2003; 32: 2-8.
25. Wood E, Kerr T, Montaner JS, et al. Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis 2004; 4:301-6.
26. Kerr T, Stoltz JA, Tyndall M, et al. Impact of a medically supervised safer injection facility on community drug use patterns: A before and after study. BMJ 2006; 332:220-2.
27. Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and former injection drug users report of HIV risk behaviors during periods of incarceration. Subst Abus 2001; 22:209-16.
28. Milloy MJ, Wood E, Small W, et al. Incarceration experiences in a cohort of active injection drug users. Drug Alcohol Rev 2008; 27:693-9.
29. Orsi MM, Brochu S. [The place of syringe exchange programs in reducing harm in Canadian prisoners]. Can J Public Health 2009; 100:29-31.
30. Buxton JA, Yu A, Kim PH, et al. HCV co-infection in HIV positive population in British Columbia, Canada. BMC Publ Health 2010; 10:225.
31. Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology 2013; 57:881-9.
32. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: An expanding epidemic. AIDS 2009; 23:F1-7.
33. Danta M, Dusheiko GM. Acute HCV in HIV-positive individuals - a review. Curr Pharm Des 2008; 14:1690-7.
34. Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother 2010; 65:4-9.
35. Wright TL, Hollander H, Pu X, et al. Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology 1994; 20:1152-5.
36. Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: A systematic review. Sex Transm Infect 2012; 88:558-64.
37. Richardson D, Fisher M, Sabin CA. Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis 2008; 197:1213-4.
38. van de Laar T, van der Bij A, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196:230-8.
39. Jin F, Prestage G P, Matthews G, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: Data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010; 86:25-8.
40. Matthews G V, Pham ST, Hellard M, et al. Patterns and characteristics of hepatitis C transmission clusters among HIVpositive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis 2011; 52:803-11.
41. Acute hepatitis C in HIV-infected individuals: Recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25:399-409.
42. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men. Clin Infect Dis 2012; 55:279-90.
43. Klein MB, Saeed S, Yang H, et al. Cohort profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. Int J Epidemiol 2010; 39:1162-9.
44. Andonov A, Chaudhary RK. Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol 1994; 32:2031-4.
45. de Bruijne J, Schinkel J, Prins M, et al. Emergence of hepatitis C virus genotype 4: Phylogenetic analysis reveals three distinct epidemiological profiles. J Clin Microbiol 2009; 47:3832-8.
46. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31:777-82.
47. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis 2001; 33:562-9.
48. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14:949-53.
49. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26:1-5.
50. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS 2008; 22:1979-91.
51. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: A prospective cohort study. J Infect Dis 2008; 198:683-6.
52. Rosenthal E, Salmon-Ceron D, Lewden C, et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 2009; 10:282-9.
53. Salmon-Ceron D, Rosenthal E, Lewden C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalite 2005 study. J Hepatol 2009; 50:736-45.
54. Giordano T P, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med 2004; 164:2349-54.
55. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100:56-63.
56. Merchante N, Merino E, Lopez-Aldeguer J, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013; 56:143-50.
57. Brau N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J Hepatol 2007; 47:527-37.
58. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96:179-83.
59. Kwong JC, Crowcroft NS, Campitelli MA, et al. Ontario Burden of Infectious Disease Study (ONBOIDS): An OAHPP/ICES Report. Toronto: Ontario Agency for Health Protection and Promotion, Institute for Clinical Evaluative Sciences, 2010.
60. Werb D, Wood E, Kerr T, Hershfield N, Palmer RW, Remis RS. Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026. Int J Drug Policy 2011; 22:70-6.
61. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55.
62. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepatitis 2003; 10:118-25.
63. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-13.
64. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004; 18:2039-45.
65. Shafran SD. Early initiation of antiretroviral therapy: The current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44:551-6.
66. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
67. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. February 12, 2013; 1-267. (Accessed February 27, 2013).
68. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012;(13 Suppl 2):1-85.
69. Clumeck N, d'Arminio Monforte A, Arribas JR, et al. European AIDS Clinical Society. Guidelines: Clinical Management and Treatment of HIV-infected adults in Europe. Version 6.1 - November 2012. (Accessed January 5, 2013).
70. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196:670-6.
71. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine. AIDS 2004; 18:767-74.
72. Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 2009; 4:e4517.
73. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
74. Nunez M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. J Hepatol 2006; 44(1 Suppl):S132-39.
75. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:426-31.
76. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186:23-31.
77. Servoss JC, Kitch DW, Andersen JW, Reisler RB, Chung RT, Robbins GK. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43:320-3.
78. Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29:41-8.
79. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-902.
80. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
81. Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012; 13:127-31.
82. Nelson M, Amaya G, Clumeck N, et al. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials. J Antimicrob Chemother 2012; 67:2020-8.
83. Clotet B, Clumeck N, Katlama C, Nijs S, Witek J. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: Pooled 96 week results from the phase III DUET trials. J Antimicrob Chemother 2010; 65:2450-4.
84. Rachlis A, Clotet B, Baxter J, Murphy R, Lefebvre E. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials 2007; 8:213-20.
85. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-48.
86. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
87. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-93.
88. Nunez M, Rios P, Martin-Carbonero L, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30:65-8.
89. Torti C, Lapadula G, Puoti M, et al. Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER Cohort. J Acquir Immune Defic Syndr 2006; 41:180-5.
90. Beld M, Penning M, van Putten M, et al. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion. Blood 1999; 94:1183-91.
91. Soriano V, Mocroft A, Rockstroh J, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198:1337-44.
92. Hull MW, Rollet K, Odueyungbo A, et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54:1798-805.
93. Claassen CW, Diener-West M, Mehta SH, Thomas DL, Kirk GD. Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis 2012; 54:1806-13.
94. Uberti-Foppa C, De Bona A, Galli L, et al. Liver fibrosis in HIVpositive patients with hepatitis C virus: Role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 2006; 41:63-7.
95. Kleiner DE. The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. Semin Liver Dis 2005; 25:52-64.
96. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-8.
97. Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 2000; 133:665-75.
98. de Ledinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010; 7:811-23.
99. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
100. Friedrich-Rust M, Ong M F, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. Gastroenterology 2008; 134:960-74.
101. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44:214-9.
102. Vergara S, Macias J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45:969-74.
103. Kirk GD, Astemborski J, Mehta SH, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-72.
104. de Ledinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010; 30:1043-8.
105. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6:375-8.
106. Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44:463-9.
107. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-25.
108. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7:40.
109. Shaheen AA, Myers R P. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008; 9:43-51.
110. de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-9.
111. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17:280-6.
112. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
113. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
114. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-13.
115. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16:352-8.
116. Vellozzi C, Buchacz K, Baker R, et al. Treatment of hepatitis C virus (HCV) infection in patients coinfected with HIV in the HIV Outpatient Study (HOPS), 1999-2007. J Viral Hepat 2011; 18:316-24.
117. Shahidullah AB, Cerulli MA, Berman DH. Interferon may cause retinopathy during hepatitis therapy. Am J Gastroenterol 1995; 90:1543.
118. Okuse C, Yotsuyanagi H, Nagase Y, et al. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C. World J Gastroenterol 2006; 12:3756-9.
119. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall M W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006; 44:1139-45.
120. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54:1137-44.
121. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
122. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-17.
123. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
124. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
125. Buti M, Agarwal K, Horsmans Y, et al. Noninferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV-infected patients. The Liver Meeting 2012: American Association for the Study of Liver Diseases (AASLD) 63rd Annual Meeting. Boston, November 9 to 13, 2012.
126. Merck Canada Inc. Victrelis (boceprevir) Product Monograph Kirkland, QC2011.
127. Van Heeswijk RP, Boogaerts G, De Paepe E, et al. The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir (abstract PK-19). Presented at: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Cambridge, June 22 to 23, 2011.
128. Sulkowski M, Pol S, Cooper C, et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: End of treatment (week-48) interim results (abstract 47). Program and abstracts of the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5 to 8, 2012.
129. Dieterich D, Soriano V, Sherman K, et al. Telaprevir in combination with pegylated interferon-α-2a+RBV in HCV/HIV-co-infected patients: A 24-week treatment interim analysis (abstract 46). Program and abstracts of the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5 to 8, 2012.
130. Slim J, Mallolas J, Pol S, al. E. Response to antiretroviral therapy is maintained during concomitant use of boceprevir + peginterferon/ribavirin in a phase IIb study of HIV/HCV co-infected patients (abstract WEPE 053). Program and abstracts of the XIX World AIDS Conference. Washington, DC: July 22 to 27, 2012.
131. Sulkowski M, Sherman K, Soriano V, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results (abstract 1408454). Program and abstracts of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, November 9 to 13, 2012.
132. Bronowicki J P, Davis M, Flamm S, et al. Sustained virologic response (SVR) in prior pegintereron/ribavirin (PR) treatment failures after retreatment with boceprevir (BOC)-+-PR: The PROVIDE Study interim results. 47th Annual Meeting of the European Association for the Study of the Liver. Barcelona, April 18 to 22, 2012. J Hepatol 2012; 56(Suppl 2):S6.
133. Cotte L, Braun J, Lascoux-Combe C, et al. High early virologic response with telaprevir-pegylated interferon-ribavirin in treatment-experienced HCV genotype 1/HIV co-infected patients (abstract 36). ANRS HC26 TelapreVIH Study. Program and abstract of the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3 to 6, 2013.
134. Poizette-Martin I, Bellissant E, Piroth L, et al. ANRS-HC27 BocepreVIH interim analysis: High early virologic response with boceprevir + pegylated interferon + ribivirin in hepatitis C virus/HIV co-infected patients with previous failure to pegylated interferon + ribivirin (abstract 37). Program and abstract of the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3 to 6, 2013.
135. Vachon ML, Factor SH, Branch AD, et al. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol 2011; 54:41-7.
136. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir with pegylated interferon/ribavirin in patients co-infected with chronic hepatitis C virus and HIV-1: Week-24 interim analysis of the TMC435-C212 Study (abstract 154LB). Program and abstract of the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3 to 6, 2013.
137. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004; 292:2839-48.
138. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
139. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. AIDS Res Hum Retroviruses 2007; 23:972-82.
140. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
141. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology 2007; 46:971-81.
142. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357:124-34.
143. Pérez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-8.
144. Voigt E, Schulz C, Klausen G, et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. J Infect 2006; 53:36-42.
145. Zanini B. Abstract 27. Program and abstracts of the Second International Workshop on HIV & Hepatitis Co-infection. Amsterdam, January 12 to 14, 2006.
146. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. HIV Med 2006; 7:248-54.
147. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-17.
148. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-9.
149. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-89.
150. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-7.
151. Boesecke C, Rockstroh JK. Treatment of acute hepatitis C infection in HIV-infected patients. Curr Opin HIV AIDS 2011; 6:278-84.
152. Nomura H, Sou S, Tanimoto H, et al. Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trial. Hepatology 2004; 39:1213-9.
153. Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48:650-8.
154. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-8.
155. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58(RR-4):1-207.
156. Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother 2010; 54:1647-9.
157. Vispo E, Barreiro P, Pineda JA, et al. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008; 13:429-37.
158. Laufer N, Laguno M, Perez I, et al. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther 2008; 13:953-7.
159. Mira JA, Lopez-Cortes LF, Barreiro P, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008; 62:1365-73.
160. Amorosa VK, Slim J, Mounzer K, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antiviral Ther 2010; 15:91-9.
161. Berenguer J, von Wichmann MA, Quereda C, et al. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. J Antimicrob Chemother 2011; 66:2843-9.
162. Van den Eynde E, Quer J, Cubero M, et al. Abacavir co-administration does not interfere with the suppressive activity of ribavirin in an HCV replicon system (abstract 963). Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, February 27 to March 2, 2011.
163. Andrade A, Hendrix C, Fuchs E, et al. Steady-state plasma and intracellular ribavirin concentrations are not significantly altered by abacavir co-administration in hepatitis C virus infected patients (abstract 538). The 20th Conference of Retroviruses and Opportunistic Infections. Atlanta, March 3 to 6, 2013.
164. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. Federal register 2012:1-239.
165. Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: An update on new interactions between HIV and non-HIV Drugs. Curr Infect Dis Rep 2012; 14:67-82.
166. Kiser J, Burton J, Anderson P, Everson G. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55:1620-8.
167. Vance DE, Mugavero M, Willig J, Raper JL, Saag MS. Aging with HIV: A cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care 2011; 22:17-25.
168. Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010; 15:413-23.
169. Vertex Pharmaceuticals Inc. Incivek (telaprevir) Product Monograph. Cambridge, MA2011.
170. Hulskotte EG, Feng H-P, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir (abstract 771LB). The 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5 to 8, 2012.
171. Schwarze-Zander C, Rockstroh JK. HIV protease inhibitors in combination with boceprevir: Are drug-drug interactions the same for all patients? AIDS 2012; 26:1845-6.
172. Van Heeswijk RP, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers (abstract 119). The 18th Conference on Retroviruses and Opportunistic Infections. Boston, February 27 to March 2, 2011.
173. Kakuda TN, Leopold L, Nijs S, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir: A randomised, two-way crossover trial (abstract O-18). The 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, April 16 to 18, 2012
174. Schering Corporation, a subsidiary of Merck & Co. Victrelis (boceprevir) Product Monograph. Whitehouse Station, New Jersey, 2011.
175. Hammond K, Wolfe P, Burton J, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers (abstract O-15). The 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, April 16 to 18, 2012.
176. Rhee E, Feng H, Xuan F, et al. Absence of a significant pharmacokinetic interaction between the hepatitis C protease inhibitor boceprevir and the HIV-1 NNRTI rilpivirine (abstract 537). The 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3 to 6, 2013.
177. de Kanter C, Blonk M, Colbers A, Fillekes Q, Schouwenberg B, Burger D. The influence of the HCV protease inhibitor boceprevir on the pharmacokinetics of the HIV integrase Inhibitor raltegravir (abstract 772LB). Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5 to 8, 2012.
178. Van Heeswijk RPG, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers (abstract A1-1738a). The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 17 to 20, 2011.
179. Moreno A, Quereda C, Montes M, et al. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir. J Acquir Immune Defic Syndr 2012; 61:e47-49.
180. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
181. Gilead Sciences Canada Inc. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Product Monograph. Mississauga, November 26, 2012.
182. Johnson M, Borland J, Chen S, Savina P, Wynne B, Piscitelli S. The effect of boceprevir and telaprevir on dolutegravir pharmacokinetics, in healthy adult subjects (abstract O-16). The 14th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, April 22 to 24, 2013.
183. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of boceprevir: Metabolism, excretion, and drug-drug interactions (abstract 118). The 18th Conference on Retroviruses and Opportunistic Infections. Boston, February 27 to March 2, 2011.
184. Van Heeswijk R, Gysen V, Googaerts G, et al. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigational HCV protease inhibitor telaprevir (abstract A-966). The 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, October 25 to 28, 2008.
185. Vourvahis M, Plotka A, Kantaridis C, Fang A, Heera J. The effect of boceprevir and telaprevir on the pharmacokinetics of maraviroc: An open-label, fixed-sequence study in healthy volunteers (abstract O-17). The 14th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, April 22 to 24, 2013.
186. Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: An update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012; 14:67-82.
187. Van Heeswijk RPG, Vandevoorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir (abstract PK-18). The 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Cambridge, June 22 to 23, 2011.
188. Luo X, Trevejo J, Van Heeswijk R P. No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers (Abst). Presented at: HEP DART. Koloa, December 4 to 8, 2011.
189. Hulskotte EG, Feng H-P, Bruce RD, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy (abstract PK-09). The 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Cambridge, June 27 to 28, 2012.
190. Cooper CL. Managing the side events of therapy. In: Shiffman ML, ed. Chronic Hepatitis C Virus: Advances in Treatment. Promise for the Future. New York: Springer, 2012; 171-82.
191. Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 2013; 57:974-84.
192. Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006; 42:1674-8.
193. Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008; 36:250-5.
194. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010; 52:1225-31.
195. Talal AH, Liu RC, Zeremski M, et al. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. J Acquir Immune Defic Syndr 2011; 58:261-8.
196. Fontaine H, Hezode C, Dorival C, et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC) (abstract 60). The 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013). Amsterdam, April 24 to 28, 2013.
197. Miro JM, Torre-Cisnero J, Moreno A, et al. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. Enferm Infecc Microbiol Clin 2005; 23:353-62.
198. O'Grady J, Taylor C, Brook G. Guidelines for liver transplantation in patients with HIV infection (2005). HIV Med 2005;(6 Suppl 2):149-53.
199. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007; 84:563-71.
200. Miro JM, Aguero F, Laguno M, et al. Liver transplantation in HIV/hepatitis co-infection. J HIV Ther 2007; 12:24-35.
201. Sugawara Y, Tamura S, Kokudo N. Liver transplantation in HCV/HIV positive patients. World J Gastrointest Surg 2011; 3:21-8.
202. Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: A systematic review and meta-analysis with synthetic cohort. AIDS 2011; 25:777-86.
203. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study. Am J Transplant 2012; 12:1866-76.
204. Anadol E, Beckebaum S, Radecke K, et al. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat 2012; 2012:197501.
205. Seden K, Back D. Directly acting antivirals for hepatitis C and antiretrovirals: Potential for drug-drug interactions. Curr Opin HIV AIDS 2011; 6:514-26.
206. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: Implications for HIV and transplant patients. Ann Hepatol 2012; 11:179-85.
207. Hulskotte EG, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and the calcineurin inhibitors cyclosporine and tacrolimus (abst). Presented at HEP DART. Koloa, December 4 to 8, 2011.
208. Garg V, Van Heeswijk R P, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-7.
209. Saxena V, Terrault N. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 2012; 17:216-24.
210. Charlton M. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - A potentially lethal cocktail. Hepatology 2011; 54:3-5.
211. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: A proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139:493-8.
212. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.
213. Vierling J, Flamm S, Gordon S, et al. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: The PROVIDE Study (abstract 931). Programs and abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, November 4 to 8, 2011.
214. Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir (abstract PK-13). Presented at the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy. Cambridge, June 22 to 23, 2011.